CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
NEUROSHIELD aims to improve the quality of life for Parkinson's disease patients by developing a novel small molecule that targets neuroinflammation through an unexplored pathway. This approach seeks to provide a safer and more effective treatment option compared to existing non-steroidal anti-inflammatory drugs.
Parkinson’s disease (PD) affects 8.5 million individuals worldwide according to WHO estimates. PD remains cureless and treatments are based on administration of dopamine precursors or analogues.
Neuroinflammation is a central hallmark of PD, however, no molecule is present in the market to tackle neuroinflammation in PD patients.
Neuroinflammation contributes to the exacerbation of the disease, as the release of inflammatory signals leads to reduced neuronal fitness driving to neuronal death. NE…
UNIVERSIDADE NOVA DE LISBOA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
